Research Program on Emerging and Re-emerging Infectious Diseases
Development of optimal medical care network for the diagnosis and treatment of tropical and parasitic diseases in Japan
Research Representative Doctor: Professor, Haruhiko Maruyama (National University Corporation University of Miyazaki)
As of April 2015, the Japan Agency for Medical Research and Development has been the contractor of the research group.
In 1980, this research group was established to create optimal medical care networks for rare imported and domestic parasitic diseases in Japan. The research group has been directly and indirectly involved in the approval and extension of 13 medications for tropical and parasitic/protozoan diseases (Table 1).
In Japan, patients with tropical diseases overseas and after returning to their home countries are sometimes noted. Some medications used to treat tropical diseases are not available in Japan because the number of such cases is extremely low to allow pharmaceutical companies to supply them on a commercial basis.
In 1980, the Ministry of Health, Labour and Welfare (MHLW) led the discussion of this problem, and the research group was established to address it.
We are supplying domestically unapproved drugs (Table 2) for severe malaria, toxoplasmosis (without HIV infection), and fascioliasis in the clinical research framework.
Table 1. Medications that were once approved in Japan and handled by the research group.
|General name||Approval month||Indications|
|Mebendazole||March, 1988||Whipworm infection|
|Praziquantel||September,1988||Clonorchiasis, paragonimiasis, metagonimiasis|
|Pentamidine isethionate||March, 1989||Pneumocystis pneumonia|
|Mefloquine||October, 2001||Malaria (treatment, prophylaxis)|
|Ivermectin||August, 2002||Strongyloidiasis, scabies|
|Atovaquone/proguanil||December, 2012||Malaria (treatment, prophylaxis)|
|Paromomycin||December, 2012||Intestinal entamoebiasis|
|Metronidazole, intravenous||July, 2014||Entamoebiasis, anaerobic infection|
|Primaquine||March, 2016||Malaria (prevent relapse)|
|Artemether/lumefantrine||December, 2016||Malaria (treatment)|
*No longer available
Table 2. Medications stored by the research group (February 2023).
|Severe malaria||Quinine gluconate, intravenous|
* Approved in Japan but not approved for toxoplasmosis combined with pyrimethamine.
Website maintained by the MHLW that discloses information on clinical research (jRCT)
Efficacy and safety of injectable quinine in patients (Injectable quinine for malaria)
Efficacy and safety of pyrimethamine/sulfadiazine/folinate combination therapy for the treatment of disseminated toxoplasmosis and toxoplasma encephalitis (Treatment of disseminated toxoplasmosis/toxoplasma encephalitis with pyrimethamine/sulfadiazine)
Efficacy and safety of pyrimethamine/sulfadiazine/folinate combination therapy for the treatment of ocular toxoplasmosis (Treatment of ocular toxoplasmosis with pyrimethamine/sulfadiazine)
Efficacy and safety of pyrimethamine/sulfadiazine/folinate combination therapy for the treatment of fetal toxoplasmosis (Treatment of fetal toxoplasmosis with pyrimethamine/sulfadiazine)
Efficacy and safety of pyrimethamine/sulfadiazine/folinate combination therapy for the treatment of congenital toxoplasmosis (Treatment of congenital toxoplasmosis with pyrimethamine/sulfadiazine)
Efficacy and safety of triclabendazole for the treatment of fasciolosis (Egaten study)